Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights
$24,750.00   |  '

Congenital Heart Block – Executive Insights – Congenital Heart Block | Executive Insights | US/EU5 | 2022

Login to access report north_east
Buy report north_east

Congenital heart block (CHB), also known as atrioventricular block, is a rare heart block disorder in which maternal antibodies attack the impulse-generating heart muscles of fetuses and newborns. Minimizing the deterioration of heart muscles and preventing disease progression are the key treatment goals in CHB. No therapies are approved for CHB, and patients are managed with off-label drugs such as dexamethasone and IVIG, or through plasmapheresis and pacemaker implantation. In addition, no commercial pharmacotherapies are in the pipeline for CHB. A major unmet need is for effective therapies and represents a commercial opportunity for drug developers in this market.

QUESTIONS ANSWERED

  • What is the diagnosed incidence of CHB?
  • What is the current market landscape including the diagnostic and management practices
  • What are the current therapy and emerging therapy landscapes?
  • What is the estimated cost of treatment in different geographies?
  • What are the key unmet needs in the management of CHB?
  • What are the key market drivers and limiters?
  • What are the opinions of KOLs on different aspects of CHB?

PRODUCT DESCRIPTION

Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.

GEOGRAPHY: United States, EU5

PRIMARY RESEARCH: 13 KOL interviews from November 2021 to January 2022

KEY DRUGS COVERED: Dexamethasone, intravenous immune globulin (IVIG)

Table of contents

Buy report north_east
Login to access report north_east

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a condition heavily treated with an array of drug classes. Although the MDD drug market is dominated by generic therapies, the heterogeneous response of MDD…
north_east
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
north_east
Report
Obesity / Overweight – Geographic Focus: China – China In-Depth – Obesity / Overweight
Obesity is recognized as a chronic disease and public health crisis globally. The primary goal of treatment is to improve obese patients’ health outcomes and quality of life. Unlike other highly…
north_east
Report
Gastroesophageal Cancer – Geographic Focus: China – China In-Depth – Gastroesophageal cancer
China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…
north_east
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east